Hepatitis C in Drug and Alcohol Settings

People who inject drugs represent approximately 90% of newly acquired hepatitis C (HCV) infections.?This course aims to provide?addiction physicians, general practitioners, nurse practitioners, and other practitioners working in Drug and Alcohol settings?with the skills and knowledge to diagnose HCV, manage comorbidities and treat HCV. 

This course is for: Addiction medicine physicians, general practitioners, nurse practitioners, and other practitioners prescribing or intending to prescribe s85?DAA?medication for HCV in alcohol and other drug settings in Australia. 

This activity has been approved by the RACGP as a?CPD?accredited?activity and has been allocated 40 CPD points. 

 

06 November 2021 7:00am – 10:00am (AWST) 

 

This event is sponsored by AbbVie. Sponsorship is governed by our Sponsorship Policy and the sponsor has no control over content, tone, emphasis, allocation of funds or selection of recipients. ASHM does not endorse or promote any sponsor’s product or service. 

 
Flyerhttps://file-us.clickdimensions.com/ashmorgau-apflc/files/20211106_hepatitiscindrugandalcoholsettings_flyer.pdf?1631855664236target=%E2%80%9D_blank%E2%80%9D  

Registerhttps://www.ashm.org.au/eventinforeg2/?id=e9b39fdf-6f17-ec11-b6e6-002248149f76  

Event Details

November 6 - November 6
07:00 AM - 10:00 AM
Chronic Conditions

Organizer Details

Disclaimer

While the Australian Government Department of Health has contributed to the funding of this website, the information on this website does not necessarily reflect the views of the Australian Government and is not advice that is provided, or information that is endorsed, by the Australian Government. The Australian Government is not responsible in negligence or otherwise for any injury, loss or damage however arising from the use of or reliance on the information provided on this website.